SequelSEC

ABEONA THERAPEUTICS INC. ABEO

Pharmaceutical Preparations · CIK 0000318306 · Fiscal year ends 1231

Revenue
$25.52M
Fiscal year ended 2026-06-30
Operating income
-$83.62M
Fiscal year ended 2026-06-30
Free cash flow
-$81.53M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$273.25MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$4.79Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / net income3.8×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue47.0×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.7×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Net margin1223.1%99th
CapEx / revenue137.0%95th
Long-term debt / equity0.05x13th
FCF margin-1448.5%20th
SBC / revenue185.2%76th
Effective tax rate0.1%24th
Operating margin-1536.9%29th
Current ratio6.93x69th
R&D / revenue460.7%65th
Gross margin73.7%55th

ABEONA THERAPEUTICS INC. (ABEO) reported revenue of $25.52M and net income of -$62.89M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from ABEONA THERAPEUTICS INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ABEONA THERAPEUTICS INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$25.52M
Cost of revenue$8.40M
Gross profit$17.12M
Operating income-$83.62M
Net income-$62.89M
Research & development$25.50M
Weighted-average diluted sharesUnavailable
Pretax income-$78.30M
Income tax expense-$15.41M
Diluted EPSUnavailable
Selling, general & administrative$73.43M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

ABEONA THERAPEUTICS INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$56.23M
Total assets$179.51M
Current assets$164.58M
Total liabilities$51.45M
Current liabilities$24.81M
Total equity incl. NCI$128.06M
Temporary (mezzanine) equityUnavailable
Inventory$5.92M
Accounts receivable$9.39M
GoodwillUnavailable
Long-term debt$1.66M
Accounts payable$2.99M

Cash flow

ABEONA THERAPEUTICS INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$76.44M
Capital expenditures$5.09M
Investing cash flow-$34.42M
Financing cash flow$3.22M
Net change in cash-$107.64M
Stock-based compensation$11.57M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$2.79M

Derived

ABEONA THERAPEUTICS INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$81.53M
Gross margin67.1%
Operating margin-327.6%
FCF margin-319.5%
SBC / revenue45.4%
Current ratio6.63x
Revenue YoY growthUnavailable
Net margin-246.4%
R&D / revenue99.9%
CapEx / revenue19.9%
Long-term debt / equity0.01x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ABEO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-17View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.